We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Takeda Pharmaceutical Company announced the completion of its previously-announced sale of a portfolio of select products sold in Latin America to Hypera S.A. for a total value of $825 million. This divestment agreement was first announced in March 2020.